Author

Mariana Mancini

NYU Langone Health

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Addison G. StameyiD· 1 shared Adrienne D. CoxiD· 1 shared Alec J. VaughaniD· 1 shared Andrew J. AguirreiD· 1 shared Andrew M. WatersiD· 1 shared Antje SchaeferiD· 1 shared Brian Matthew WolpiniD· 1 shared Channing J. DeriD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Addison G. StameyORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer

Wen-Hsuan Chang, Alec J. Vaughan, Addison G. Stamey, Mariana Mancini, Makiko Hayashi, Runying Y. Yang, Ryan N. Robb, Daniel Andrussier, Jeffrey A. Klomp, Andrew M. Waters, Antje Schaefer, Brian Matthew Wolpin, Kirsten L. Bryant, Adrienne D. Cox, Fernando Moreira Simabuco, , Channing J. Der

This study identifies KEAP1 loss as a resistance mechanism to KRAS inhibitors in pancreatic and lung cancer and shows that combining glutamine inhibition with KRAS inhibitors can overcome this resistance.

bioRxiv · Apr 21, 2026 · PreprintCancer Biology